Quel now prescribes GLP-1s for addiction.

Patients gain access ahead of definitive evidence, paying a commercial subscription for unproven use.

GLP-1 receptors reach the brain’s reward circuitry, so researchers are testing whether appetite-blunting drugs curb craving broadly, and off-label prescribing is legal.

Dozens of trials on GLP-1s and substance use are still enrolling, with no results yet.

Sources: STAT